In the CIRCAN-NEC pilot study, circulating tumor DNA (ctDNA) was evaluated during the course of a patient’s therapy and in the context of their mutational status (BRAF, KRAS, RB, etc). This evidence concerns the gene RB1 and neuroendocrine carcinoma.